Tratamento
Wondering when your doctor might recommend pausing Ozempic? Here's what the science says about treatment interruptions, what happens to your body, and how to restart safely.
Brazil's EMS Farmacêutica has launched a domestically manufactured semaglutide pen, marking the first locally produced GLP-1 receptor agonist in this format. Here's what you need to know about pricing, availability, and how it compares to Ozempic.
Head-to-head trials like SURPASS-2 give us real data on how these two popular diabetes medications stack up against each other on HbA1c, weight loss, and safety.
While tirzepatida acts on two receptors simultaneously and semaglutida targets only one, the best choice depends on each patient's clinical profile and medical guidance.
Curious about switching from Ozempic to an EMS generic semaglutide in Brazil? Learn what differentiates them, what ANVISA approval means, and what to discuss with your doctor.
Brazil's medical council issued a formal warning about unregistered tirzepatide. Here's what this alert means for healthcare providers and patients seeking GLP-1 treatments.
Eli Lilly is exploring an oral version of tirzepatide, but peptide pills face significant scientific hurdles. Here's what we know about the possibility of a Mounjaro or Zepbound pill.
If you're looking into Mounjaro (tirzepatide) in the United States, you've probably noticed the confusing maze of pricing, prescriptions, and online offers. Here's what you actually need to know.
Hypera Pharma's new Semavy pen enters Brazil's GLP-1 market at a competitive price point. Here's what to consider before making the switch.
Starting on Ozempic at 0.25 mg can feel like nothing is happening. Here's what science says about dose titration, individual response, and when to talk to your doctor about adjustments.
